361 related articles for article (PubMed ID: 35203336)
1. Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.
Ghasemi M; Emerson CP; Hayward LJ
Cells; 2022 Feb; 11(4):. PubMed ID: 35203336
[TBL] [Abstract][Full Text] [Related]
2. Facioscapulohumeral muscular dystrophy: the road to targeted therapies.
Tihaya MS; Mul K; Balog J; de Greef JC; Tapscott SJ; Tawil R; Statland JM; van der Maarel SM
Nat Rev Neurol; 2023 Feb; 19(2):91-108. PubMed ID: 36627512
[TBL] [Abstract][Full Text] [Related]
3. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
4. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
5. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
Jagannathan S
Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
7. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
8. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
9. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
10. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
[TBL] [Abstract][Full Text] [Related]
11. Current Therapeutic Approaches in FSHD.
Wang LH; Tawil R
J Neuromuscul Dis; 2021; 8(3):441-451. PubMed ID: 33579868
[TBL] [Abstract][Full Text] [Related]
12. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells.
Lim KRQ; Yokota T
Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032
[TBL] [Abstract][Full Text] [Related]
13. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
14. The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy.
Bouwman LF; van der Maarel SM; de Greef JC
Curr Opin Neurol; 2020 Oct; 33(5):635-640. PubMed ID: 32796277
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.
Cohen J; DeSimone A; Lek M; Lek A
Trends Mol Med; 2021 Feb; 27(2):123-137. PubMed ID: 33092966
[TBL] [Abstract][Full Text] [Related]
16. A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics.
Campbell AE; Arjomand J; King OD; Tawil R; Jagannathan S
J Neuromuscul Dis; 2023; 10(6):1031-1040. PubMed ID: 37899061
[TBL] [Abstract][Full Text] [Related]
17. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
Schätzl T; Kaiser L; Deigner HP
Orphanet J Rare Dis; 2021 Mar; 16(1):129. PubMed ID: 33712050
[TBL] [Abstract][Full Text] [Related]
18. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
19. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
20. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]